… reductions in drug costs and average patient copayments (9). … ’ baseline knowledge concerning
market entry for biosimilars … oncology biosimilar relative to a growth hormone biosimilar …

… biosimilars, due to lack of knowledge. These findings are consistent with an incomplete
understanding of biosimilars… Drug Administration (FDA, the USA regulatory agency) that did not …

… , among women of this older age group in the United States, … biologic have extensive
knowledge about the manufacturing … In contrast, oncologists should be aware of “noncomparable …

… the determination of biosimilar status, such as knowledge of the … than 500 US hematologists
and oncologists found that73: … Patients who were aware of biosimilars were more likely to …

… pharmacists’ knowledge and perceptions of biosimilars to … A better understanding of biosimilars
amongst pharmacists … , bevacizumab, and rituximab in oncology is better compared with …

… response to specific pathogens or cancer antigens). Biologic drugs … understanding of the
issues associated with biosimilars to … are not interchanged without the full knowledge of the …

… US; this article therefore aims to increase understanding of the … This article aims to increase
understanding of the biosimilars … A high level of prior knowledge of the reference product is …

… Currently, this knowledge often is limited 19, 20. … The majority of respondents were aware
that biosimilar monoclonal … who started Pfizer in November 2012 as the oncology biosimilars …

… to biosimilars in Latin America, specifically for patients with breast cancer and colorectal
cancer, for whom biosimilars … The USA did not implement a regulatory framework for biosimilar …

… or similar biologic therapeutic, co-administration of other … Awareness of biosimilars is low
among patients, with gaps in … ) and patient registries will add to our knowledge concerning …